Discover and read the best of Twitter Threads about #Bebtelovimab

Most recents (7)

Status of the latest #COVID19 Wave in #NewYork #BellwetherState

NY just uploaded 425 sequences - had to update charts!

Top circulating variants - BA.5.2.1 (20%), BA.4.6 (15%)

Proportion of BQ* lineages are increasing
BQ.1* (2.84%) & BQ.1.1* (1.00%)👀 ImageImage
BQ.1.1 (aka #Cerberus) is able to evade all available mAb therapeutics including #Evusheld and #Bebtelovimab.

Bivalent boosters (OG/Omicron.BA.5) will potentially protect the boosted from getting severe disease.

Please get #boosted ASAP! Image
We may have to switch to #SequenceToTreat from #TestToTreat soon...

mAbs work well against BA.2.3.20

#Bebtelovimab works well against most BA.2.75* without spike K444 mutations

None of the mAb currently authorized by @US_FDA will work against BQ.1. lineage
Read 4 tweets
Lineages to watch

1. BQ.1*
2. BQ1.1*
3. BA.2.75.2*
4. XBB - Recombinant of BJ.1 and BM.1.1.1
5. BA.2.3.20

All lineages have appreciable ACE2 affinity;
1-4 are highly immune evasive;
1 & 2 evade many therapeutics - #Evusheld and #Bebtelovimab

fortune.com/well/2022/09/2…
Credits to Lineage Spotters/Proposers

BA.2.3.20 - @LongDesertTrain
BQ.1*/BQ.1.1* - @siamosolocani
BA.2.75.2 - @agamedilab
XBB - @CorneliusRoemer

and the #LineageWatch team for 24/7 tracking & monitoring

cov-spectrum.org/collections/24…
BA.2.3.20 [ ⛳️to track Convergent Mutations]

@PangoNetwork Proposal/Background

H/T @LongDesertTrain

github.com/cov-lineages/p…
Read 7 tweets
今週の国際製薬ニュース
色々ありましたが最後のオチはFDA

先にオチから。
現在オミクロン対応ワクチン!と各社が宣伝しているものは、中身は2020β株対応ワクチンであるのは指摘してきた通りです。
各社のHP見てください。よく見るとそう書いてたり、論文にはっきり書いてたり、開発記号に2020入って
たり
E484Kに対する抗体ができることが大事(従来株でできる抗体の効果にして約半分がここ)なので、β対応ワクチンでもある程度オミクロンへ交差すると分かってきたと。

そこへFDAがSTATEMENTを出しました。
ワクチン開発各社へ、「オミクロンBA1対応成分だけでなく、

fda.gov/news-events/pr…
BA4/5対応成分も含めよ。二価ワクチンにしなさい。支援するよ」

は?そもそも今開発されている「対オミクロンワクチン」はβ対応ワクチンなんだが?

と最初思いましたが、ま、対応成分という言い方が妙で、要するにβ対応ワクチンでの交差期待はここに含まれるのでしょう。
Read 31 tweets
New #PANGO designations - BA.2.*

BA.2.4Alias of B.1.1.529.2.4, #Singapore lineage

BA.2.5Alias of B.1.1.529.2.5, lineage in #Portugal and other countries

BA.2.6Alias of B.1.1.529.2.6, lineage in #France and other countries

BA.2.7Alias of B.1.1.529.2.7, #USA lineage ImageImage
These are new designations - branching from the BA.2 subvariant

more to follow ..... will update key mutational differences and transmission advantage (if any)
BA.2.4 (aka B.1.1.529.2.4) | prevalent in Singapore

Key mutation: ORF6:M58K

COV-spectrum predicts a growth advantage of 14% over BA.2 and 46% over BA.1.1 in #Singapore

BA.2 and BA.1.1 are currently the dominant lineages in circulation in Singapore Image
Read 29 tweets
Recap settimanale su Covid: vediamo quello che è successo. Segue un thread con alcuni punti importanti, nel caso in cui ve li foste persi. Let's go!
1/n 🧵 #COVID19
Da una valutazione approfondita delle infezioni da BA.2 (>124.000 persone) vs BA.1 (>30.000) in Qatar sembrerebbe che BA.2 abbia cariche virali più elevate e periodi infettivi più lunghi. medrxiv.org/content/10.110… 2/n
Hong Kong ha i decessi pro capite più alti al mondo causa Covid e continua a crescere. Preoccupante. 3/n
Read 16 tweets
👉👁️Variante BA.2, cada vez se conocen más detalles, no buenos. El monoclonal Sotrovimab, uno de nuestros únicos monoclonales, como tratamiento de Omicron, parece no efectivo con BA.2
👉👁️Evusheld parece no funcionar también con BA.2 Noticia, que esperemos no se confirme, supone un revés para los inmunodeprimidos. Realmente es marzo el momento de levantar toda restricción?
👉Los inmunodeprimidos responden de manera muy dispar a las vacunas, de ahí que necesiten tratamientos (monoclonales, antivirales), para poder vivir más tranquilos.
Read 5 tweets
BA.2 is a sublineage of Omicron that's replacing the original BA.1 version in the U.S. I'll break down what we know about its effects on current antivirals and the facts behind #bebtelovimab, the newest anti-SARS-CoV-2 monoclonal antibody (mAb) that received FDA EUA. a🧵 1/
Compared to BA.1, BA.2 has quite a few changes to ORF1ab and the NTD region of Spike. Luckily, I don't see any mutations in nsp5 or 12 that would affect Paxlovid, remdesivir, or molnupiravir activity 2/
The other good news pertains to Evusheld (tix/cil). It took a hit vs BA.1/BA.1.1, but based on data from David Ho's group (biorxiv.org/content/10.110…), BA.2 has almost no effect on cilgavimab (CoV2-2130, blue box). This is great news for Evusheld and for our immunosuppressed pts 3/
Read 12 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!